| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We identified the complement 1q (C1q) as a target antigen of the anti-endothelial cell autoantibodies in the serum samples of patients with neuromyelitis optica spectrum disorders (NMOSD) by immunoprecipitation using cultured human brain microvascular endothelial cell as the antigen source, followed by LC/MS/MS analysis. Serum anti-C1q autoantibody levels during the acute phase of NMOSD patients correlated with the CSF/serum albumin ratio, which is a marker of brood brain barrier (BBB) integrity. Then, we compared serum anti-C1q autoantibody levels between the 11 patients with NMDAR encephalitis and 15 healthy subjects. Serum anti-C1q autoantibody levels in patients with NMDAR encephalitis were significantly higher than those in healthy subject. We speculate that increased serum anti-C1q autoantibody levels are associated with BBB permeability, and contribute to pathogenic autoantibody influx into the CNS of autoimmune encephalitis.
|
